Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Regeneron Pharmaceuticals
Memorial Sloan Kettering Cancer Center
Regeneron Pharmaceuticals
University of Chicago
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Ohio State University Comprehensive Cancer Center
Grey Wolf Therapeutics
OncoNano Medicine, Inc.
University of Pittsburgh
Regeneron Pharmaceuticals
M.D. Anderson Cancer Center
Bolt Biotherapeutics, Inc.
UNC Lineberger Comprehensive Cancer Center
Maastricht University Medical Center
Palleon Pharmaceuticals, Inc.
Sensei Biotherapeutics, Inc.
Rakuten Medical, Inc.
Vyriad, Inc.
Regeneron Pharmaceuticals
ISA Pharmaceuticals
ISA Pharmaceuticals
OncoResponse, Inc.
M.D. Anderson Cancer Center
Jules Bordet Institute
University of Miami
Silverback Therapeutics
Oncovir, Inc.